Dr. Daniel CHRISTIAEN has decades of experience in business development, finances and administration of innovative scientific companies. He obtained his PhD in Biochemistry in 1986 as a Permanent Researcher at CNRS in the University of Lille. After his postdoctoral training at the Ben Gurion University (Israel) he set up his first biotechnology company, Pronatec (Lille, France). Subsequently he contributed to the creation of several biotech companies, and, in 2000, following the merging of Valigen with a German and an American company he became a member of the Board of Directors of the Valigen Group. Later he created Genoscreen (Lille, France). During the recent past he has been instrumental in raising funds on behalf of scientific and medical foundations in Lyon and Geneva. In 2008 he was elected Deputy at the City Hall of Le Touvet (Grenoble, France), as «Head of Economic Development» of his town. Dr. Daniel Christiaen acts as Managing Director of Animascope.

           
   

Dr. Arnaud BRIAT  is a biologist with years of experience in the fields of biomedical research and molecular imaging. He obtained his PhD in Biomedical Engineering in 2003 at INSERM U877 “Radiopharmaceuticals Bioclinicals”, Joseph Fourier University (Grenoble, France). This laboratory focuses on the development of new radiotracers for the diagnosis, the prognostic and therapy of mainly cardiovascular diseases, metabolism alterations (diabetes), neurodegenerative diseases and oncology in Nuclear Medicine. He also obtained the University Diploma authorizing the supervision of animal experimentation from Claude Bernard University and the School of Veterinary Medicine (Lyon, France). From 2003, he joined a Cancer Research UK clinical center in London where he actively participated to the design of transgenic models for the optical and nuclear in vivo imaging of gene expression. He was also involved in the development of innovative therapeutic approaches in oncology (viral gene therapy) and in the evaluation of current PET tracers for the assessment of tumor response to therapy. After two years as the manager of the oncology group (back at INSERM U877 in 2008), Dr Arnaud Briat acts as Scientific Project Manager of Animascope.

Bibliography

Françoise BORSON CHAZOT is Professor at the Univ. of Lyon and at the Nuclear Medicine Unit of the Hospital Neuro-Cardiologique of the same city. Specialist in endocrine oncology is author of several scientific publications.

Jacques DEMONGEOT is Professor at the Univ. of Grenoble and at the Hospital of the same city. Moreover, being Director of the TIMC-IMAG laboratory of Grenoble, he is a specialist of medical informatics, biomatematics and cognition modeling.

Jacques DESCOTES is Head of the Poison Control and Toxicovigilance Centre of Lyon. Author of many publications on immunotoxicology, he is an expert of clinical and pre-clinical safety for health products.

Georges HAOUR is Professor of Technology & Innovation Management at IMD (Switzerland). He is also partner of Sagentia (Cambridge, UK) and adviser to corporations & organisations, particularly in the healthcare sector.

Patrick HARDY is Director of Animal Science & Welfare at Merial R&D (Lyon) and former Director of Animal Science & Welfare at Sanofi-Aventis (Paris). He has been also Scientific Director Europe for Veterinary Services at Charles River Laboratories.

Osman RATIB is Professor at the University of Geneva. He is Specialist FMH in cardiology, nuclear medicine and biomedical imaging. He is also head of the Clinical Unit of Nuclear Medicine at the University Hospital of Geneva.

Mohamed SLAOUI works on Drug Safety Evaluation, as Senior Toxicologic Pathologist at Sanofi-Aventis (Paris). Before, he has been Toxicologic Pathologist and Study Director at Organon. He has organized conferences and courses, including Europola 2009.

Dr. Mimoun NEJJARI is a specialist in experimental oncology and the management of clinical trials. He has a PhD in cellular and molecular biology, obtained from the INSERM laboratory at the Denis Diderot University (Paris). During his PhD thesis on cellular and molecular biology, he contributed to the development of animal models of human gastrointestinal oncology and the corresponding anti-cancer therapeutic protocols. Dr. Nejjari is also an expert in animal experimentation. He obtained the Diploma for Experimentation and Practice of Surgery on animals from the Claude Bernard University and the School of Veterinary Medicine of Lyon. In addition, in 2001 he received the Diploma of Investigator of Clinical Trials from the Claude Bernard University in Lyon and in 1997 he received the Diploma of Pharmacology from the Denis Diderot University in Paris. Dr. Nejjari is the President and the Operating Officer of Animascope.

Bibliography